Prognostic role of monocyte-to-high-density lipoprotein ratio in mortality of VTE patients at Ardabil (2023-2024).

Abstract

Background: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of cardiovascular mortality. The monocyte-to-high-density lipoprotein ratio (MHR) is a novel inflammatory biomarker with potential prognostic value in VTE.

Methods: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of cardiovascular mortality. The monocyte-to-high-density lipoprotein ratio (MHR) is a novel inflammatory biomarker with potential prognostic value in VTE.

Results: The mortality rate was 9%. Higher MHR was significantly associated with mortality (adjusted OR: 1.102, 95% CI: 1.013-1.199, P = 0.023), indicating a 10.2% increased mortality risk per unit increase in MHR. No significant associations were found with hospital stay duration (P = 0.238, R² = 0.007), CT-scan findings (P = 0.60), or echocardiography results (P = 0.40).

Conclusion: MHR may serve as a predictor of mortality in patients with VTE, offering a cost-effective tool for risk stratification. These findings support its potential use in identifying high-risk patients for targeted interventions. Prospective studies are needed to validate and extend these results.